novel coronavirus pneumonia (COVID-19)
Conditions
Interventions
Group A:alpha-Interferon atomization
Group B:Lopinavir and Ritonavir + alpha-Interferon atomization
Group C:Favipiravir + alpha-Interferon atomization
Sponsors
The Third People's Hospital of Shenzhen
Eligibility
Sex/Gender
All
Age
16 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. 16 to 75 years of age, male or female; 2. Respiratory or blood samples tested positive for novel coronavirus; 3. Within 7 days of onset: Onset is defined as body temperature exceeding 38 degree C (armpit temperature) or at least one 2019-nCoV pneumonia related systemic or respiratory symptom; 4. Willing to take contraception during the study and within 7 days after treatment; 5. No difficulty in swallowing the Pills; 6. Willing to sign informed consent form.
Exclusion criteria
Exclusion criteria: 1. Any situation which the protocol cannot be carried out safely; 2. Patient refuses to receive invasive tracheal support (if needed); 3. Pregnant or lactating women:childbearing age women with positive pregnancy test, breastfeeding, miscarriage or within 2 weeks after delivery.Postmenopausal and hysterectomy women do not need a pregnancy test; 4. Patients with chronic liver and kidney disease and reaching end-stage; 5. Previous history of allergic reactions to Fapiravir or Lopinavir and Ritonavir; 6. Currently or in the past 28 days, participated in another clinical trial against novel coronavirus treatment; 7. After the investigator's judgment, the subjects could not participate the study protocol, follow-up or self-evaluation after enrollment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Declining speed of Novel Coronavirus by PCR;Negative Time of Novel Coronavirus by PCR;Incidentce rate of chest imaging;Incidence rate of liver enzymes;Incidence rate of kidney damage; | — |
Countries
China
Contacts
Public ContactLiu Yingxia
The Third People's Hospital of Shenzhen
Outcome results
None listed